Quarterly ResultJun 22, 2026, 09:11 AM
INVO Fertility Q1 Revenue +23% to $2.0M; Strengthens Balance Sheet
AI Summary
INVO Fertility reported strong financial results for Q1 2026, with revenue increasing 23% to $2.0 million, driven by organic growth and the acquisition of Family Beginnings. The company significantly strengthened its balance sheet by eliminating all Series C-2 Preferred Stock and warrant liabilities, leading to a 108% increase in stockholders' equity to $15.0 million. Despite a net loss from continuing operations of $(5.5) million (which included a $3.8 million non-cash loss), the company improved its cash position and reduced total liabilities, positioning itself for future growth through its focused fertility strategy.
Key Highlights
- Revenue increased 23% to $2,015,225 for Q1 2026 compared to Q1 2025.
- Consolidated clinic revenue grew 22% to $1,982,233.
- Net loss from continuing operations was $(5.5) million, including a $3.8M non-cash loss.
- Adjusted EBITDA was $(1.26) million, reflecting investments for expansion.
- All Series C-2 Preferred Stock and warrant liabilities were eliminated by March 31, 2026.
- Stockholders' equity increased 108% to $15.0 million ($9.16 per share).
- Cash increased to $4.9 million at March 31, 2026, from $2.1 million at Dec 31, 2025.
- Total liabilities decreased 26% to $9.6 million; current liabilities decreased 39% to $6.4 million.
Price Impact
More from IVF